Proteomics in Small Cell Lung Cancer

Launched by AALBORG UNIVERSITY HOSPITAL · Nov 14, 2022

Keywords

ClinConnect Summary

This clinical trial, titled "Proteomics in Small Cell Lung Cancer," is studying how certain proteins found in tiny particles released by tumors can help us understand small cell lung cancer (SCLC) better. The goal is to collect information from patients who have just been diagnosed with this type of cancer to see how these proteins behave and what they can tell us about the disease. By learning more, researchers hope to improve the way SCLC is treated in the future.

If you or a loved one has recently been diagnosed with small cell lung cancer and is between the ages of 65 and 74, you may be eligible to participate in this study. To join, participants must be able to receive standard chemotherapy, which includes specific medications called carboplatin and etoposide. During the trial, participants will undergo tests and scans to measure the disease and provide samples to help researchers. It's important to know that those with other active cancers or who have received prior cancer treatments may not qualify. This study is currently looking for new patients to join, and your participation could contribute to valuable research that may help others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written and signed informed consent
• • Histopathologically and/or cytologically newly-diagnosed SCLC
• • Measurable disease on CT scans
• • Eligibility to receive standard chemotherapy consisting of carboplatin and etoposide
• Exclusion Criteria:
• • Active biopsy-verified second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ
• • Prior treatment for any malignant diseases other than non-melanoma skin cancer and cervical carcinoma in situ
• • Concomitant anticoagulation treatment (acetylsalicylic acid and clopidogrel are allowed)
• • Treatment with any other investigational agent